GlassScriptPhysician profile
Orazio Bartolomeo
NPI 1558368803
$26,092.97
in general payments reported to CMS, 2019-2025
62 companies · $3,393 in 2025
The $3,393 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,118 · 2020: $2,812 · 2021: $4,571 · 2022: $3,882 · 2023: $4,071 · 2024: $4,245 · 2025: $3,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,534.77 |
| Education | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,137.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,632.02 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,266.17 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $2,168.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $1,996.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,705.25 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $1,505.07 | 2019-2025 | |
| Lilly USA, LLC | $1,429.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $623.95 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novartis Pharmaceuticals Corporation | $540.34 | 2019-2024 | |
| Amarin Pharma, INC. | $525.63 | 2019-2022 | |
| Exact Sciences Corporation | $522.70 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $477.83 | 2019-2023 | Trintellix |
| Allergan, INC. | $461.08 | 2019-2022 | |
| Lundbeck LLC | $378.02 | 2022-2025 | Rexulti |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orazio Bartolomeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.